Status:
COMPLETED
PRP Efficacy and Safety in BPF
Lead Sponsor:
Guangzhou Institute of Respiratory Disease
Conditions:
Bronchopleural Fistula
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Platelet-rich plasma(PRP), is a concentrate of platelet-rich plasma protein derived from whole blood. The main components of it are platelets, leukocytes and fibrin. Autologous PRP treatment can avoid...
Eligibility Criteria
Inclusion
- Subjects with aged between 18 to 75
- Subjects diagnosed with bronchopleural fistula (the sizes of the fistulas less than 4mm)
- Subjects willing to accept PRP treatment
Exclusion
- Subjects with fistulas larger than 4mm
- Subjects who cannot tolerate bronchoscopy due to severe cardiac disease or other major comorbidities
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
April 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 25 2024
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05304897
Start Date
April 16 2022
End Date
January 25 2024
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510120